全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Multiple Sclerosis: Is Clinical Efficacy Sidetracked by Health Economics?

DOI: 10.3923/jeth.2012.91.98

Full-Text   Cite this paper   Add to My Lib

Abstract:

This study investigates the claim that clinical efficacy of drugs and related interventions for Multiple Sclerosis (MS) are side tracked by financial cost and economic efficiency considerations. In addressing this central question and its practical implications, the study reviewed relevant pharmacoeconomic studies generated from online medical/scientific databases with attention devoted to the literature on discontinued/failed clinical trials. A survey of these trials was also conducted using registries from the National Institutes of Health (NIH) and National Multiple Sclerosis Society in the United States. Survey results were tabulated and analyzed. The study sustains the validity of the initial claim concerning financial and economic considerations only to the extent that theoretical debates have extended and departed from the traditional scope and objectives of clinical efficacy. However, the same claim should be substantively qualified where it concerns actual applications and impact of cost and efficiency studies on discontinuing (or initiating) clinical testing and efficacy data collection for MS. The study suggests that expanded notions of clinical efficacy do not necessarily affect decisions to initiate or discontinue clinical trials for MS drugs but could help broaden or enhance our understanding of disease management options for MS sufferers.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133